Multi-Kinase Inhibitor with or without Atezolizumab in Previously Treated Liver Cancer - Clinical Trial

or email

gi-oncology-cru@dm.duke.edu

What is the Purpose of this Study?

We are doing this study to compare the effectiveness of atezolizumab + a multi-kinase inhibitor (either cabozantinib or lenvatinib) versus a multi-kinase inhibitor alone.

What is the Condition Being Studied?

Hepatocellular Carcinoma

Who Can Participate in the Study?

Adults who:

Have hepatocellular carcinoma (a type of liver cancer)
Received exactly 1 previous line of therapy, which must have been atezolizumab + bevacizumab

For more information about who can join this study, please contact the study team at john.d.gibbs@duke.edu.

Age Group

Adults

What is Involved?

If you choose to join this study, you will:

Take one of the study drugs, either cabozantinib or lenvatinib, by mouth once per day
Receive the study drug atezolizumab through an IV once every 3 weeks (if assigned)
Return to the clinic every 3 weeks so we can monitor your health
Give blood and urine for testing
Get CT or MRI scans every 9 weeks

You may be on the study drugs for up to 2 years.

Study Details

Full Title

[ACCRU-GI-2008] A Phase II Randomized Study of Atezolizumab plus Multi-Kinase Inhibitor versus Multi-Kinase Inhibitor Alone in Subjects with Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab

Principal Investigator